Literature DB >> 12020265

Risk factors for cognitive impairment in HIV-1-infected persons with different risk behaviors.

Diana De Ronchi1, Irma Faranca, Domenico Berardi, Paolo Scudellari, Marco Borderi, Roberto Manfredi, Laura Fratiglioni.   

Abstract

CONTEXT: Although it is well established that acquired immunodeficiency syndrome dementia complex mainly develops in patients with advanced human immunodeficiency virus 1 (HIV-1) infection and severe immunosuppression, other factors that might increase the risk of early neuropsychological abnormalities are controversial.
OBJECTIVE: To identify risk factors for HIV-1-related cognitive impairment.
DESIGN: Case-control study.
SETTING: Division of Infectious Diseases, University of Bologna. PARTICIPANTS: We studied 272 consecutive individuals: 90 HIV-1-seronegative, 88 asymptomatic HIV-1-seropositive, and 94 symptomatic HIV-1-seropositive persons. MAIN OUTCOME MEASURES: Cognitive impairment was defined as poor performance on at least 2 of the 7 neuropsychological tests included in the battery. Cutoff scores for poor performance on a test were established as 2 or more SDs lower than the mean of the seronegative group in the corresponding risk behavior strata: injecting drug users, hemophiliacs, and other risk behaviors. The following risk factors were studied: age, sex, education, risk behaviors, HIV-1 stage, lymphocyte count, and antiretroviral therapy.
RESULTS: Compared with individuals with higher levels of education, those with less than 6 years of schooling had an odds ratio (OR) of 17.2 (95% confidence interval [CI], 3.6-83.3) for cognitive impairment, independent of age, sex, disease stage, antiretroviral therapy, and risk behavior. Compared with injecting drug users, homosexual/bisexual and heterosexual participants had ORs of 9.6 (95% CI, 2.2-42.7) and 6.3 (95% CI, 2.2-18.3), respectively, for cognitive impairment. Use of antiretroviral treatment (any vs none) was associated with lower prevalence of cognitive impairment (OR, 0.1; 95% CI, 0.0-0.3). Compared with persons with high CD4+ cell counts (> or =500/microL), those with low (<200/microL) and moderate (200-499/microL) CD4+ cell counts had adjusted ORs of 8.6 (95% CI, 1.0-71.0) and 6.9 (95% CI, 1.0-48.4), respectively. The presence of prominent depressive symptoms did not change the results.
CONCLUSIONS: Low educational level, low CD4+ cell count, and homosexual/bisexual and heterosexual risk behaviors are risk factors for cognitive impairment in HIV-1-seropositive persons. Antiretroviral therapy exerts a beneficial effect against cognitive impairment in symptomatic individuals. Homosexual/bisexual and heterosexual persons who survive longer are expected to be the group at highest risk for cognitive impairment. However, the protective effect of antiretroviral therapy may balance this increased risk.

Entities:  

Mesh:

Year:  2002        PMID: 12020265     DOI: 10.1001/archneur.59.5.812

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  20 in total

1.  Socioeconomic Status and Neuropsychological Functioning: Associations in an Ethnically Diverse HIV+ Cohort.

Authors:  Alyssa Arentoft; Desiree Byrd; Jennifer Monzones; Kelly Coulehan; Armando Fuentes; Ana Rosario; Caitlin Miranda; Susan Morgello; Monica Rivera Mindt
Journal:  Clin Neuropsychol       Date:  2015-04-14       Impact factor: 3.535

2.  Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.

Authors:  Hamza Coban; Kevin Robertson; Marlene Smurzynski; Supriya Krishnan; Kunling Wu; Ronald J Bosch; Ann C Collier; Ronald J Ellis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

3.  Mixed membership trajectory models of cognitive impairment in the multicenter AIDS cohort study.

Authors:  Samantha A Molsberry; Fabrizio Lecci; Lawrence Kingsley; Brian Junker; Sandra Reynolds; Karl Goodkin; Andrew J Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor; James T Becker
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

4.  Diagnostic Utility of the International HIV Dementia Scale for HIV-Associated Neurocognitive Impairment and Disorder in South Africa.

Authors:  Karl Goodkin; David J Hardy; Dinesh Singh; Enrique Lopez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2014       Impact factor: 2.198

5.  Transcranial sonography of the third ventricle and cognitive dysfunction in HIV patients.

Authors:  Ozgür Yaldizli; Oliver Kastrup; Mark Obermann; Stefan Esser; Hans Wilhelm; Christian Ley; Michael Forsting; Matthias Maschke
Journal:  J Neurol       Date:  2006-09-21       Impact factor: 4.849

6.  Screening for HIV-associated dementia in South Africa: potentials and pitfalls of task-shifting.

Authors:  Reuben N Robbins; Robert H Remien; Claude A Mellins; John A Joska; Dan J Stein
Journal:  AIDS Patient Care STDS       Date:  2011-09-15       Impact factor: 5.078

7.  Characterization and sociocultural predictors of neuropsychological test performance in HIV+ Hispanic individuals.

Authors:  Monica Rivera Mindt; Desiree Byrd; Elizabeth L Ryan; Reuben Robbins; Jennifer Monzones; Alyssa Arentoft; Kaori Kubo Germano; Debra E Henniger; Susan Morgello
Journal:  Cultur Divers Ethnic Minor Psychol       Date:  2008-10

Review 8.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Understanding the neuropsychological profile of HIV+ participants with low literacy: role of the General Ability Measure for Adults (GAMA).

Authors:  Elizabeth L Ryan; Desiree Byrd; Monica Rivera Mindt; William J Rausch; Susan Morgello
Journal:  Clin Neuropsychol       Date:  2008-04-21       Impact factor: 3.535

10.  Neuropsychological phenotypes among men with and without HIV disease in the multicenter AIDS cohort study.

Authors:  Samantha A Molsberry; Yu Cheng; Lawrence Kingsley; Lisa Jacobson; Andrew J Levine; Eileen Martin; Eric N Miller; Cynthia A Munro; Ann Ragin; Ned Sacktor; James T Becker
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.